Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Investment analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of ImmunityBio in a research note issued on Tuesday, August 4th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.06) per share for the quarter, up from their prior forecast of ($0.07). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for ImmunityBio’s Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.40) EPS, FY2029 earnings at $0.94 EPS and FY2030 earnings at $1.39 EPS.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million during the quarter, compared to the consensus estimate of $49.70 million.

A number of other equities analysts have also recently commented on the stock. D. Boral Capital reissued a “buy” rating and issued a $23.00 price target on shares of ImmunityBio in a research note on Tuesday, May 5th. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Friday, July 10th. Finally, BTIG Research reaffirmed a “buy” rating and set a $12.00 price objective on shares of ImmunityBio in a report on Thursday, May 21st. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, ImmunityBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.20.

ImmunityBio Stock Performance

Shares of IBRX stock opened at $7.25 on Thursday. The firm’s 50-day simple moving average is $7.66 and its two-hundred day simple moving average is $7.64. ImmunityBio has a 52 week low of $1.95 and a 52 week high of $12.43. The firm has a market cap of $7.59 billion, a price-to-earnings ratio of -7.47 and a beta of 0.03.

Hedge Funds Weigh In On ImmunityBio

Institutional investors and hedge funds have recently made changes to their positions in the business. Western Wealth Management LLC bought a new position in shares of ImmunityBio during the first quarter valued at about $44,000. Geneos Wealth Management Inc. boosted its stake in shares of ImmunityBio by 579.3% during the first quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock valued at $44,000 after purchasing an additional 4,907 shares during the period. Archer Investment Corp boosted its stake in shares of ImmunityBio by 67.1% during the first quarter. Archer Investment Corp now owns 5,872 shares of the company’s stock valued at $45,000 after purchasing an additional 2,358 shares during the period. Fifth Third Bancorp grew its holdings in shares of ImmunityBio by 3,372.2% in the second quarter. Fifth Third Bancorp now owns 7,500 shares of the company’s stock worth $66,000 after purchasing an additional 7,284 shares during the last quarter. Finally, Hodges Capital Management Inc. purchased a new position in shares of ImmunityBio in the first quarter worth $77,000. Institutional investors own 8.58% of the company’s stock.

Insider Buying and Selling

In other ImmunityBio news, Director Cheryl Cohen sold 131,210 shares of ImmunityBio stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total transaction of $1,246,495.00. Following the transaction, the director directly owned 125,386 shares of the company’s stock, valued at approximately $1,191,167. This trade represents a 51.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $7.88, for a total transaction of $197,000.00. Following the completion of the sale, the director owned 2,802,788 shares of the company’s stock, valued at approximately $22,085,969.44. The trade was a 0.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 435,443 shares of company stock worth $3,918,819 in the last quarter. 66.10% of the stock is owned by insiders.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Record Anktiva-driven revenue growth: ImmunityBio reported second-quarter net product revenue of $50.7 million, up 92% year over year and 15% sequentially. First-half revenue reached $94.8 million, a 121% increase, indicating continued commercial adoption of Anktiva. ImmunityBio Reports Record Q2 2026 Net Product Revenue
• Positive Sentiment: Revenue exceeded expectations: Quarterly revenue of $51.24 million surpassed the $49.70 million analyst consensus, with coverage highlighting strong Anktiva uptake and additional regulatory milestones ahead. IBRX Q2 Earnings and Sales Beat Estimates
• Neutral Sentiment: Analyst outlook remains bullish but estimates are mixed: HC Wainwright reiterated its “Buy” rating and $15 price target. It raised Q3 2026 and Q4 2026 EPS forecasts slightly and increased its FY2027 estimate to $0.07, but lowered FY2026 EPS to $(0.40) from $(0.28), FY2029 to $0.94 from $0.95, and FY2030 to $1.39 from $1.41.
• Negative Sentiment: Reported earnings miss: ImmunityBio posted a quarterly loss of $(0.22) per share, well below the consensus loss estimate of $(0.08), despite beating on revenue. The earnings shortfall triggered a gap-down reaction and highlights ongoing profitability risk as the company expands commercialization. ImmunityBio Shares Gap Down After Earnings Miss

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.